Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity

Kamat, S and Kumari, M (2021) Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity. In: Frontiers in Pharmacology, 12 .

	PDF fro_pha_12_2021 - Published Version Download (1MB)
Preview	Image (GIF) fphar-12-576093-g001 (1).gif - Published Supplemental Material Download (3kB) | Preview

Abstract

Chloroquine and its derivatives have been used since ages to treat malaria and have also been approved by the FDA to treat autoimmune diseases. The drug employs pH-dependent inhibition of functioning and signalling of the endosome, lysosome and trans-Golgi network, immunomodulatory actions, inhibition of autophagy and interference with receptor binding to treat cancer and many viral diseases. The ongoing pandemic of COVID-19 has brought the whole world on the knees, seeking an urgent hunt for an anti-SARS-CoV-2 drug. Chloroquine has shown to inhibit receptor binding of the viral particles, interferes with their replication and inhibits �cytokine storm�. Though multiple modes of actions have been employed by chloroquine against multiple diseases, viral diseases can provide an added advantage to establish the anti�SARS-CoV-2 mechanism, the in vitro and in vivo trials against SARS-CoV-2 have yielded mixed results. The toxicological effects and dosage optimization of chloroquine have been studied for many diseases, though it needs a proper evaluation again as chloroquine is also associated with several toxicities. Moreover, the drug is inexpensive and is readily available in many countries. Though much of the hope has been created by chloroquine and its derivatives against multiple diseases, repurposing it against SARS-CoV-2 requires large scale, collaborative, randomized and unbiased clinical trials to avoid false promises. This review summarizes the use and the mechanism of chloroquine against multiple diseases, its side-effects, mechanisms and the different clinical trials ongoing against �COVID-19�. © Copyright © 2021 Kamat and Kumari.

Item Type:	Journal Article
Publication:	Frontiers in Pharmacology
Publisher:	Frontiers Media S.A.
Additional Information:	The copyright for this article belongs to Authors
Department/Centre:	Division of Biological Sciences > Biochemistry
Date Deposited:	22 Jul 2021 10:42
Last Modified:	22 Jul 2021 10:42
URI:	http://eprints.iisc.ac.in/id/eprint/68874

Actions (login required)

View Item